Patients
ascites, drug allergies, malignancy, pericardial effusions, hypersensitivity
DISEASE PROGRESSION, ASCITES, METASTASIS, DRUG ALLERGIES, ADVERSE EVENTS, INTERSTITIAL PNEUMONIA, PERIPHERAL NEUROPATHY, PERICARDIAL EFFUSIONS, SOLID TUMOR, ONCOLOGY, PLEURAL EFFUSIONS, RECURRENT NSCLC, HYPERSENSITIVITY
The criteria for patient eligibility included an age of 20 years or older, diagnosis of advanced or recurrent NSCLC confirmed histologically or cytologically, within 12 weeks after PD‐(L)1 inhibitor (single or combination therapy) treatment failure due to disease progression or unacceptable adverse events, an Eastern Cooperative Oncology Group performance status (ECOG‐PS) of 0–2, and measurable lesions according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.The key exclusion criteria included patients who had a history of severe drug allergies or hypersensitivity to nab‐paclitaxel or albumin; had been previously treated with solvent‐based paclitaxel or nab‐paclitaxel; were receiving more than 10 mg of systemic prednisolone or an equivalent amount of another corticosteroid at the time of registration; had Grade 2 or higher peripheral neuropathy; had interstitial pneumonia (apparent on chest X‐ray); had pleural effusions, ascites, and/or pericardial effusions requiring drainage; had symptomatic central nerve metastasis; received therapeutic or palliative radiation therapy within 2 weeks of study Day 1; underwent major surgery within 4 weeks of study Day 1; had a concurrent active malignancy; were lactating/breastfeeding; had a positive pregnancy test; and/or were positive for hepatitis B surface antigen(s).